Both semaglutide and tirzepatide are labelled for three injection sites: the abdomen, the thigh and the upper arm. Both labels also state that similar drug exposure was achieved across all three, so the choice of site does not change the dose that reaches the bloodstream.
That settles the question most people are actually asking, and it moves the interesting part elsewhere. If the site does not affect absorption, then rotation, depth and skin condition are what the instructions are about. Here is what each label says, where the products differ from each other, and what the evidence behind the rotation advice actually is.
- Abdomen, thigh and upper arm are the labelled sites for both molecules.
- The labels report similar exposure across sites. Semaglutide's absolute bioavailability is 89% and tirzepatide's is 80%, neither broken out by site.
- Wegovy's label adds that site and time of day can change with no dosage modification. The tirzepatide labels describe the upper arm as a site someone else injects.
- Rotation exists to protect the tissue, not the dose. Repeated injection into one area is linked to lipohypertrophy, which does distort absorption once it forms.
- Injection site reactions were reported by 1.4% of Wegovy patients and 3.2% of Mounjaro patients in placebo-controlled trials.
The three sites, product by product
The wording is not identical across labels, and the differences are the part worth reading rather than the shared list of three.
| Product | Labelled sites | Upper arm | Rotation | Dose change when switching site |
|---|---|---|---|---|
| Wegovy (semaglutide) | Abdomen, thigh, upper arm | Listed without a condition | Rotate with each dose | None. The label says site and time of day can change without modification |
| Mounjaro (tirzepatide) | Abdomen, thigh, back of upper arm | Described as injected by another person | Rotate with each dose | None specified |
| Zepbound (tirzepatide) | Abdomen, thigh, back of upper arm | Described as injected by another person | Rotate with each dose | None specified |
The upper arm difference is easy to miss and it is a real one. The tirzepatide labels frame the back of the upper arm as a site another person administers, which makes practical sense for a spot you cannot see or reach comfortably. The semaglutide label lists it alongside the other two. Neither is a safety warning about the tissue, it is a statement about who is holding the pen.
Everything below the site list, meaning how to hold the device, how long to hold it against the skin and what to check before injecting, is in the Instructions for Use that ships with each specific pen. Those differ between products and between the single-dose and multi-dose versions of the same product, which is why this article does not attempt to summarise them.
Why the site does not change the dose
Injection site matters a great deal for rapid-acting insulin, where the drug has to work within a meal, and the assumption carries over to GLP-1 drugs where it does not apply. The pharmacokinetics are the reason.
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Absolute bioavailability | 89% | 80% |
| Time to peak concentration | Days rather than hours after dosing | Median 24 hours, range 8 to 72 hours |
| Elimination half-life | About one week | About 5 to 6 days |
| Exposure by site | Similar in abdomen, thigh, upper arm | Similar in abdomen, thigh, upper arm |
| Dosing interval | Once weekly | Once weekly |
A drug that peaks a day or more after injection and then clears over the best part of a week is not sensitive to small differences in local blood flow. Any variation the site introduces is absorbed into a curve that is already flat by design. This is also why neither label attaches a timing instruction to the injection: both allow any time of day, with or without meals.
The practical consequence is that someone who used the abdomen for six months and switches to the thigh has not changed their dose. Nothing on either label suggests otherwise, and the semaglutide label says so explicitly.
What rotation is actually for
If the site does not affect absorption, the instruction to rotate with each dose needs a different explanation, and it has one.
Lipohypertrophy is a thickened, rubbery area of subcutaneous fat that develops where injections are repeatedly given in the same place. The international injection technique recommendations produced by the Forum for Injection Technique and Therapy, written and reviewed by 183 experts from 54 countries, describe it as a frequent complication of injection therapy that distorts absorption, advise that injections should not be given into these lesions, and identify correct site rotation as the way to prevent them (PMID 27594187).
Note the order of cause and effect. A healthy site does not change absorption. A site damaged by repeated injection does. Rotation is therefore preventive maintenance on the tissue rather than a way to fine-tune the dose, and that evidence base comes from decades of insulin therapy rather than from GLP-1 trials specifically.
What the trials recorded at the injection site
Injection site reactions are a named adverse event in these programmes, and the rates are low but not identical between drugs.
| Product | On the drug | On placebo | Source |
|---|---|---|---|
| Wegovy | 1.4% | 1% | Weight-reduction trials in adults, label section 6 |
| Mounjaro | 3.2% | 0.4% | Placebo-controlled trials in adults, label section 6 |
| Tirzepatide, antibody-positive patients | 4.6% | 0.7% in antibody-negative patients | Pool of seven clinical trials |
The reactions the labels list are local and unglamorous: itching, redness, inflammation, hardening and irritation at the site. The antibody row is the most informative one. Patients who developed anti-tirzepatide antibodies reported site reactions at several times the rate of those who did not, which points at an immune response to the drug rather than at injection technique.
Reactions can also be specific to one molecule rather than to the class. A published case describes a man in his 70s who developed a rash on the lower abdomen after switching from dulaglutide to tirzepatide, which resolved after the tirzepatide was stopped, having had no reaction to the previous drug at the same site (PMID 37842452). A single case proves nothing about frequency, but it does show that a reaction to one GLP-1 is not a reaction to all of them. The broader side effect profiles are in semaglutide side effects and tirzepatide side effects.
Subcutaneous means the fat layer, not the muscle
Every product discussed here is labelled for subcutaneous injection, meaning the fat layer between skin and muscle. The FITTER recommendations state that the shortest needles available, a 4 mm pen needle and a 6 mm syringe needle at the time of writing, are safe, effective and less painful and should be first-line in all patient categories, and that intramuscular injection should be avoided.
Two honest caveats on applying that to a GLP-1. First, the specific harm FITTER attaches to intramuscular injection is severe hypoglycaemia with long-acting insulins, which is not a risk profile that transfers to a weekly incretin drug. Second, the prefilled pens these drugs come in have a fixed needle chosen by the manufacturer, so needle length is not usually a decision the person injecting makes. The recommendation matters most for anyone drawing from a vial with a separate syringe, and in that case the needle is a question for the prescriber or pharmacist who supplied it.
Injecting alongside insulin
Plenty of people with type 2 diabetes take both, and the tirzepatide label addresses it directly. The two are given as separate injections and never mixed in one syringe. They may go into the same body region, but the label specifies that the injections should not be adjacent to each other.
That is the one place where site selection carries a genuine instruction rather than a preference, and it is another reason rotation is worth taking seriously when two injected drugs are competing for the same few areas of skin.
Technique aside, what do the numbers say?
Site choice does not change the dose. Run your starting weight against the published trial averages to see what the dose itself is expected to do.
What this does not replace
- The Instructions for Use for your device. Site lists are shared across a molecule. Technique is specific to a pen or vial and is in the leaflet that came with it.
- Advice about existing skin problems. None of the above describes what to do about a site that is already tender, hardened or discoloured. That is a conversation with a prescriber or pharmacist, not a decision to make from a table.
- Dose decisions. Nothing about where an injection goes changes which dose is appropriate. The labelled schedules are in our semaglutide dosage chart and tirzepatide dosage chart, and a GLP-1 weight loss calculator covers what the dose itself is expected to do.
FAQ
Where do you inject Wegovy?
The label lists three sites: the abdomen, the thigh and the upper arm. It also says to rotate injection sites with each dose, and that the injection site and the time of day can both be changed without any dosage modification. The exact technique for a given pen is in that product's Instructions for Use.
Does the injection site change how well a GLP-1 works?
Not measurably, according to the labels. Both the semaglutide and the tirzepatide prescribing information state that similar exposure was achieved with subcutaneous administration in the abdomen, thigh or upper arm. Semaglutide's absolute bioavailability is 89% and tirzepatide's is 80%, and neither figure is broken out by site because the difference was not clinically relevant.
Can you inject a GLP-1 in the same spot every week?
The labels say to rotate sites with each dose. The reason is skin health rather than absorption: repeated injection into one spot is associated with lipohypertrophy, a thickened area of fatty tissue that distorts how drug is absorbed once it forms. International injection technique recommendations advise against injecting into such areas and identify correct site rotation as the way to prevent them.
Can you inject Mounjaro or Zepbound into your own upper arm?
The tirzepatide labels word this differently from Wegovy. They describe injection into the abdomen or thigh, or having another person inject into the back of the upper arm. The semaglutide label lists the upper arm without that condition. It is worth reading the specific label rather than assuming the three sites are interchangeable across products.
How common are injection site reactions with GLP-1 drugs?
Uncommon, and the rate differs by drug. In the Wegovy weight-reduction trials, 1.4% of treated patients reported an injection site reaction against 1% on placebo. In the placebo-controlled Mounjaro trials the figures were 3.2% against 0.4%. In a pool of seven tirzepatide trials, reactions occurred in 4.6% of patients who developed anti-tirzepatide antibodies against 0.7% of those who did not.
Should you inject a GLP-1 into fat or muscle?
These products are labelled for subcutaneous injection, which is the fat layer beneath the skin rather than the muscle below it. Injection technique recommendations based on insulin therapy advise that the shortest needles are first-line in all patient groups and that intramuscular injection should be avoided. Needle choice and technique are questions for the prescriber or pharmacist who supplied the device.
Sources
- WEGOVY (semaglutide) injection and tablets, prescribing information. Novo Nordisk. Sections 2 and 6.
- OZEMPIC (semaglutide) injection, prescribing information. Novo Nordisk. Section 12.3, pharmacokinetics.
- MOUNJARO (tirzepatide) injection, prescribing information. Eli Lilly and Company. Sections 2, 6.1 and 12.3.
- ZEPBOUND (tirzepatide) injection, prescribing information. Eli Lilly and Company. Sections 2 and 12.3.
- Frid AH, Kreugel G, Grassi G, et al. New Insulin Delivery Recommendations. Mayo Clin Proc. 2016;91(9):1231-1255. PMID: 27594187
- Mizumoto J. Tirzepatide-Induced Injection Site Reaction. Cureus. 2023;15(9):e45181. PMID: 37842452
This article is for information only and is not medical advice. Dosing, suitability and any change to treatment are decisions for your prescriber.